{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:45:42Z","timestamp":1789753542956,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The development of vaccines based on outer membrane vesicles (OMV) that naturally bud off from bacteria is an evolving field in infectious diseases. However, the inherent inflammatory nature of OMV limits their use as human vaccines. This study employed an engineered vesicle technology to develop synthetic bacterial vesicles (SyBV) that activate the immune system without the severe immunotoxicity of OMV. SyBV were generated from bacterial membranes through treatment with detergent and ionic stress. SyBV induced less inflammatory responses in macrophages and in mice compared to natural OMV. Immunization with SyBV or OMV induced comparable antigen-specific adaptive immunity. Specifically, immunization with <jats:italic>Pseudomonas aeruginosa<\/jats:italic>-derived SyBV protected mice against bacterial challenge, and this was accompanied by significant reduction in lung cell infiltration and inflammatory cytokines. Further, immunization with <jats:italic>Escherichia coli<\/jats:italic>-derived SyBV protected mice against <jats:italic>E. coli<\/jats:italic> sepsis, comparable to OMV-immunized group. The protective activity of SyBV was driven by the stimulation of B-cell and T-cell immunity. Also, SyBV were engineered to display the SARS-CoV-2 S1 protein on their surface, and these vesicles induced specific S1 protein antibody and T-cell responses. Collectively, these results demonstrate that SyBV may be a safe and efficient vaccine platform for the prevention of bacterial and viral infections.<\/jats:p>","DOI":"10.1186\/s12951-023-01928-w","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T08:02:43Z","timestamp":1684483363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Detoxified synthetic bacterial membrane vesicles as a vaccine platform against bacteria and SARS-CoV-2"],"prefix":"10.1186","volume":"21","author":[{"given":"Kyong-Su","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Svennerholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Crescitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"L\u00e4sser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inta","family":"Gribonika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bostr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Alalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M","family":"Harandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Farewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"L\u00f6tvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"1928_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/jac\/dkp201","volume":"64","author":"AA El Solh","year":"2009","unstructured":"El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother. 2009;64:229\u201338.","journal-title":"J Antimicrob Chemother"},{"key":"1928_CR2","doi-asserted-by":"publisher","first-page":"102304","DOI":"10.1016\/j.isci.2021.102304","volume":"24","author":"AR Mahoney","year":"2021","unstructured":"Mahoney AR, Safaee MM, Wuest WM, Furst AL. The silent pandemic: Emergent antibiotic resistances following the global response to SARS-CoV-2. iScience. 2021;24:102304.","journal-title":"iScience"},{"key":"1928_CR3","doi-asserted-by":"crossref","unstructured":"Bitto NJ, Kaparakis-Liaskos M. The therapeutic benefit of bacterial membrane vesicles. Int J Mol Sci 2017; 18.","DOI":"10.3390\/ijms18061287"},{"key":"1928_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nri2567","volume":"9","author":"C Thery","year":"2009","unstructured":"Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9:581\u201393.","journal-title":"Nat Rev Immunol"},{"key":"1928_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.semcdb.2015.02.006","volume":"40","author":"JH Kim","year":"2015","unstructured":"Kim JH, Lee J, Park J, Gho YS. Gram-negative and Gram-positive bacterial extracellular vesicles. Semin Cell Dev Biol. 2015;40:97\u2013104.","journal-title":"Semin Cell Dev Biol"},{"key":"1928_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrmicro3525","volume":"13","author":"C Schwechheimer","year":"2015","unstructured":"Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015;13:605\u201319.","journal-title":"Nat Rev Microbiol"},{"key":"1928_CR7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.vaccine.2018.01.034","volume":"36","author":"X Zhang","year":"2018","unstructured":"Zhang X, Yang F, Zou J, Wu W, Jing H, Gou Q, Li H, Gu J, Zou Q, Zhang J. Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice. Vaccine. 2018;36:1047\u201354.","journal-title":"Vaccine"},{"key":"1928_CR8","doi-asserted-by":"publisher","first-page":"e11334","DOI":"10.1371\/journal.pone.0011334","volume":"5","author":"KS Park","year":"2010","unstructured":"Park KS, Choi KH, Kim YS, Hong BS, Kim OY, Kim JH, Yoon CM, Koh GY, Kim YK, Gho YS. Outer membrane vesicles derived from Escherichia coli induce systemic inflammatory response syndrome. PLoS ONE. 2010;5:e11334.","journal-title":"PLoS ONE"},{"key":"1928_CR9","doi-asserted-by":"publisher","first-page":"17434","DOI":"10.1038\/s41598-017-16363-9","volume":"7","author":"K Svennerholm","year":"2017","unstructured":"Svennerholm K, Park KS, Wikstrom J, Lasser C, Crescitelli R, Shelke GV, Jang SC, Suzuki S, Bandeira E, Olofsson CS, et al. Escherichia coli outer membrane vesicles can contribute to sepsis induced cardiac dysfunction. Sci Rep. 2017;7:17434.","journal-title":"Sci Rep"},{"key":"1928_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1165\/rcmb.2012-0370OC","volume":"49","author":"KS Park","year":"2013","unstructured":"Park KS, Lee J, Jang SC, Kim SR, Jang MH, Lotvall J, Kim YK, Gho YS. Pulmonary inflammation induced by bacteria-free outer membrane vesicles from Pseudomonas aeruginosa. Am J Respir Cell Mol Biol. 2013;49:637\u201345.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1928_CR11","doi-asserted-by":"publisher","first-page":"e12120","DOI":"10.1002\/jev2.12120","volume":"10","author":"KS Park","year":"2021","unstructured":"Park KS, Svennerholm K, Crescitelli R, Lasser C, Gribonika I, Lotvall J. Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy. J Extracell Vesicles. 2021;10:e12120.","journal-title":"J Extracell Vesicles"},{"key":"1928_CR12","doi-asserted-by":"publisher","first-page":"828","DOI":"10.4161\/rna.20206","volume":"9","author":"A Dalpke","year":"2012","unstructured":"Dalpke A, Helm M. RNA mediated toll-like receptor stimulation in health and disease. RNA Biol. 2012;9:828\u201342.","journal-title":"RNA Biol"},{"key":"1928_CR13","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1128\/CVI.05223-11","volume":"18","author":"H Tian","year":"2011","unstructured":"Tian H, Fu F, Li X, Chen X, Wang W, Lang Y, Cong F, Liu C, Tong G, Li X. Identification of the immunogenic outer membrane protein A antigen of Haemophilus parasuis by a proteomics approach and passive immunization with monoclonal antibodies in mice. Clin Vaccine Immunol. 2011;18:1695\u2013701.","journal-title":"Clin Vaccine Immunol"},{"key":"1928_CR14","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3389\/fimmu.2018.01777","volume":"9","author":"B Allard","year":"2018","unstructured":"Allard B, Panariti A, Martin JG. Alveolar Macrophages in the resolution of inflammation, tissue repair, and tolerance to infection. Front Immunol. 2018;9:1777.","journal-title":"Front Immunol"},{"key":"1928_CR15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.psyneuen.2012.10.010","volume":"38","author":"JI Granger","year":"2013","unstructured":"Granger JI, Ratti PL, Datta SC, Raymond RM, Opp MR. Sepsis-induced morbidity in mice: effects on body temperature, body weight, cage activity, social behavior and cytokines in brain. Psychoneuroendocrinology. 2013;38:1047\u201357.","journal-title":"Psychoneuroendocrinology"},{"key":"1928_CR16","doi-asserted-by":"crossref","unstructured":"Shepherd FR, McLaren JE. T cell immunity to bacterial pathogens: mechanisms of Immune Control and Bacterial Evasion. Int J Mol Sci 2020; 21.","DOI":"10.3390\/ijms21176144"},{"key":"1928_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri3837","volume":"15","author":"M Kaparakis-Liaskos","year":"2015","unstructured":"Kaparakis-Liaskos M, Ferrero RL. Immune modulation by bacterial outer membrane vesicles. Nat Rev Immunol. 2015;15:375\u201387.","journal-title":"Nat Rev Immunol"},{"key":"1928_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41:529\u201342.","journal-title":"Immunity"},{"key":"1928_CR19","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41:1141\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"1928_CR20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4161\/bioe.27461","volume":"5","author":"GL Huang","year":"2014","unstructured":"Huang GL, Anderson TD, Clubb RT. Engineering microbial surfaces to degrade lignocellulosic biomass. Bioengineered. 2014;5:96\u2013106.","journal-title":"Bioengineered"},{"key":"1928_CR21","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1086\/593186","volume":"47","author":"L Martinez-Solano","year":"2008","unstructured":"Martinez-Solano L, Macia MD, Fajardo A, Oliver A, Martinez JL. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis. 2008;47:1526\u201333.","journal-title":"Clin Infect Dis"},{"key":"1928_CR22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.biotechadv.2017.05.003","volume":"35","author":"MJH Gerritzen","year":"2017","unstructured":"Gerritzen MJH, Martens DE, Wijffels RH, van der Pol L, Stork M. Bioengineering bacterial outer membrane vesicles as vaccine platform. Biotechnol Adv. 2017;35:565\u201374.","journal-title":"Biotechnol Adv"},{"key":"1928_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.addr.2017.05.003","volume":"114","author":"YMD Gnopo","year":"2017","unstructured":"Gnopo YMD, Watkins HC, Stevenson TC, DeLisa MP, Putnam D. Designer outer membrane vesicles as immunomodulatory systems - reprogramming bacteria for vaccine delivery. Adv Drug Deliv Rev. 2017;114:132\u201342.","journal-title":"Adv Drug Deliv Rev"},{"key":"1928_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jss.2014.05.007","volume":"192","author":"MC Soult","year":"2014","unstructured":"Soult MC, Dobrydneva Y, Wahab KH, Britt LD, Sullivan CJ. Outer membrane vesicles alter inflammation and coagulation mediators. J Surg Res. 2014;192:134\u201342.","journal-title":"J Surg Res"},{"key":"1928_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3389\/fmicb.2018.00783","volume":"9","author":"K Tan","year":"2018","unstructured":"Tan K, Li R, Huang X, Liu Q. Outer membrane vesicles: current status and future direction of these Novel Vaccine Adjuvants. Front Microbiol. 2018;9:783.","journal-title":"Front Microbiol"},{"key":"1928_CR26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1111\/cmi.12655","volume":"18","author":"EJ O\u2019Donoghue","year":"2016","unstructured":"O\u2019Donoghue EJ, Krachler AM. Mechanisms of outer membrane vesicle entry into host cells. Cell Microbiol. 2016;18:1508\u201317.","journal-title":"Cell Microbiol"},{"key":"1928_CR27","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1002\/pmic.201000212","volume":"11","author":"DS Choi","year":"2011","unstructured":"Choi DS, Kim DK, Choi SJ, Lee J, Choi JP, Rho S, Park SH, Kim YK, Hwang D, Gho YS. Proteomic analysis of outer membrane vesicles derived from Pseudomonas aeruginosa. Proteomics. 2011;11:3424\u20139.","journal-title":"Proteomics"},{"key":"1928_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1099\/00222615-38-2-79","volume":"38","author":"HE Gilleland","year":"1993","unstructured":"Gilleland HE, Gilleland LB, Fowler MR. Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model. J Med Microbiol. 1993;38:79\u201386.","journal-title":"J Med Microbiol"},{"key":"1928_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0928-8244(03)00094-4","volume":"37","author":"K Gocke","year":"2003","unstructured":"Gocke K, Baumann U, Hagemann H, Gabelsberger J, Hahn H, Freihorst J, von Specht BU. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS Immunol Med Microbiol. 2003;37:167\u201371.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"1928_CR30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.4161\/hv.23226","volume":"9","author":"R Moore","year":"2013","unstructured":"Moore R, Kyd JM, Carzino R, Armstrong D, Grimwood K, Otczyk DC, Cripps AW. Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection. Hum Vaccin Immunother. 2013;9:506\u201314.","journal-title":"Hum Vaccin Immunother"},{"key":"1928_CR31","doi-asserted-by":"crossref","unstructured":"Mancini F, Rossi O, Necchi F, Micoli F. OMV Vaccines and the role of TLR Agonists in Immune Response. Int J Mol Sci 2020; 21.","DOI":"10.3390\/ijms21124416"},{"key":"1928_CR32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S0264-410X(02)00546-7","volume":"21","author":"C Arigita","year":"2003","unstructured":"Arigita C, Kersten GF, Hazendonk T, Hennink WE, Crommelin DJ, Jiskoot W. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine. 2003;21:950\u201360.","journal-title":"Vaccine"},{"key":"1928_CR33","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.4049\/jimmunol.1200742","volume":"190","author":"OY Kim","year":"2013","unstructured":"Kim OY, Hong BS, Park KS, Yoon YJ, Choi SJ, Lee WH, Roh TY, Lotvall J, Kim YK, Gho YS. Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol. 2013;190:4092\u2013102.","journal-title":"J Immunol"},{"key":"1928_CR34","doi-asserted-by":"publisher","first-page":"37242","DOI":"10.1038\/srep37242","volume":"6","author":"W Huang","year":"2016","unstructured":"Huang W, Wang S, Yao Y, Xia Y, Yang X, Li K, Sun P, Liu C, Sun W, Bai H, et al. Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection. Sci Rep. 2016;6:37242.","journal-title":"Sci Rep"},{"key":"1928_CR35","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1128\/CVI.00119-14","volume":"21","author":"W Nieves","year":"2014","unstructured":"Nieves W, Petersen H, Judy BM, Blumentritt CA, Russell-Lodrigue K, Roy CJ, Torres AG, Morici LA. A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clin Vaccine Immunol. 2014;21:747\u201354.","journal-title":"Clin Vaccine Immunol"},{"key":"1928_CR36","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1002\/pmic.200700196","volume":"7","author":"EY Lee","year":"2007","unstructured":"Lee EY, Bang JY, Park GW, Choi DS, Kang JS, Kim HJ, Park KS, Lee JO, Kim YK, Kwon KH, et al. Global proteomic profiling of native outer membrane vesicles derived from Escherichia coli. Proteomics. 2007;7:3143\u201353.","journal-title":"Proteomics"},{"key":"1928_CR37","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.4049\/jimmunol.163.12.6448","volume":"163","author":"JM Brewer","year":"1999","unstructured":"Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol. 1999;163:6448\u201354.","journal-title":"J Immunol"},{"key":"1928_CR38","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1016\/j.vaccine.2019.07.103","volume":"37","author":"W Bowen","year":"2019","unstructured":"Bowen W, Batra L, Pulsifer AR, Yolcu ES, Lawrenz MB, Shirwan H. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague. Vaccine. 2019;37:5708\u201316.","journal-title":"Vaccine"},{"key":"1928_CR39","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33:492\u2013503.","journal-title":"Immunity"},{"key":"1928_CR40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1021\/nl503508h","volume":"15","author":"OY Kim","year":"2015","unstructured":"Kim OY, Choi SJ, Jang SC, Park KS, Kim SR, Choi JP, Lim JH, Lee SW, Park J, Di Vizio D, et al. Bacterial protoplast-derived nanovesicles as vaccine delivery system against bacterial infection. Nano Lett. 2015;15:266\u201374.","journal-title":"Nano Lett"},{"key":"1928_CR41","doi-asserted-by":"crossref","unstructured":"Baker SM, Davitt CJH, Motyka N, Kikendall NL, Russell-Lodrigue K, Roy CJ, Morici LA. A Burkholderia pseudomallei outer membrane vesicle vaccine provides Cross Protection against Inhalational Glanders in mice and non-human Primates. Vaccines (Basel). 2017; 5.","DOI":"10.3390\/vaccines5040049"},{"key":"1928_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0168-1656(02)00043-3","volume":"96","author":"P Samuelson","year":"2002","unstructured":"Samuelson P, Gunneriusson E, Nygren PA, Stahl S. Display of proteins on bacteria. J Biotechnol. 2002;96:129\u201354.","journal-title":"J Biotechnol"},{"key":"1928_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jmb.2008.03.076","volume":"380","author":"JY Kim","year":"2008","unstructured":"Kim JY, Doody AM, Chen DJ, Cremona GH, Shuler ML, Putnam D, DeLisa MP. Engineered bacterial outer membrane vesicles with enhanced functionality. J Mol Biol. 2008;380:51\u201366.","journal-title":"J Mol Biol"},{"key":"1928_CR44","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12934-014-0162-8","volume":"13","author":"WS Jong","year":"2014","unstructured":"Jong WS, Daleke-Schermerhorn MH, Vikstrom D, Ten Hagen-Jongman CM, de Punder K, van der Wel NN, van de Sandt CE, Rimmelzwaan GF, Follmann F, Agger EM, et al. An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines. Microb Cell Fact. 2014;13:162.","journal-title":"Microb Cell Fact"},{"key":"1928_CR45","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1194\/jlr.R070201","volume":"57","author":"S Heider","year":"2016","unstructured":"Heider S, Dangerfield JA, Metzner C. Biomedical applications of glycosylphosphatidylinositol-anchored proteins. J Lipid Res. 2016;57:1778\u201388.","journal-title":"J Lipid Res"},{"key":"1928_CR46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/protein\/9.2.239","volume":"9","author":"G Georgiou","year":"1996","unstructured":"Georgiou G, Stephens DL, Stathopoulos C, Poetschke HL, Mendenhall J, Earhart CF. Display of beta-lactamase on the Escherichia coli surface: outer membrane phenotypes conferred by lpp\u2019-OmpA\u2019-beta-lactamase fusions. Protein Eng. 1996;9:239\u201347.","journal-title":"Protein Eng"},{"key":"1928_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nbt0197-29","volume":"15","author":"G Georgiou","year":"1997","unstructured":"Georgiou G, Stathopoulos C, Daugherty PS, Nayak AR, Iverson BL, Curtiss R. 3rd. Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. Nat Biotechnol. 1997;15:29\u201334.","journal-title":"Nat Biotechnol"},{"key":"1928_CR48","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/biot.201400395","volume":"10","author":"L van der Pol","year":"2015","unstructured":"van der Pol L, Stork M, van der Ley P. Outer membrane vesicles as platform vaccine technology. Biotechnol J. 2015;10:1689\u2013706.","journal-title":"Biotechnol J"},{"key":"1928_CR49","doi-asserted-by":"publisher","first-page":"101433","DOI":"10.1016\/j.smim.2020.101433","volume":"50","author":"F Micoli","year":"2020","unstructured":"Micoli F, MacLennan CA. Outer membrane vesicle vaccines. Semin Immunol. 2020;50:101433.","journal-title":"Semin Immunol"},{"key":"1928_CR50","doi-asserted-by":"publisher","first-page":"630","DOI":"10.2174\/157016211798998772","volume":"9","author":"MR Aghasadeghi","year":"2011","unstructured":"Aghasadeghi MR, Salmani AS, Sadat SM, Javadi F, Memarnejadian A, Vahabpour R, Zabihollahi R, Moshiri A, Siadat SD. Application of outer membrane vesicle of Neisseria meningitidis serogroup B as a new adjuvant to induce strongly Th1-oriented responses against HIV-1. Curr HIV Res. 2011;9:630\u20135.","journal-title":"Curr HIV Res"},{"key":"1928_CR51","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ymthe.2017.01.010","volume":"25","author":"HC Watkins","year":"2017","unstructured":"Watkins HC, Rappazzo CG, Higgins JS, Sun X, Brock N, Chau A, Misra A, Cannizzo JPB, King MR, Maines TR, et al. Safe recombinant outer membrane vesicles that display M2e elicit Heterologous Influenza Protection. Mol Ther. 2017;25:989\u20131002.","journal-title":"Mol Ther"},{"key":"1928_CR52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nmeth.1322","volume":"6","author":"JR Wisniewski","year":"2009","unstructured":"Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359\u201362.","journal-title":"Nat Methods"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01928-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01928-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01928-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T09:06:36Z","timestamp":1684487196000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01928-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1928"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01928-w","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal treatments or procedures were approved by the local Animal Ethics Committee in Gothenburg, Sweden (permit no. Dnr 5.8.18\u201303598\/2019) and was performed under institutional animal use and care guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KSP and JL have filed multiple patents for the development of mammalian and bacterial vesicles for therapeutic purposes. JL owns equity in Codiak BioSciences Inc. and Exocure BioSciences Inc., and KSP is partly financed by Exocure Biosciences Inc. The other authors have no disclosures related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}